These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18070831)

  • 21. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.
    Arnold A; Brouse SD; Pitcher WD; Hall RG
    J Intensive Care Med; 2010 Sep; 25(5):259-70. PubMed ID: 20622257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
    Soubirou JF; Rossi B; Couffignal C; Ruppé E; Chau F; Massias L; Lepeule R; Mentre F; Fantin B
    J Antimicrob Chemother; 2015 May; 70(5):1466-72. PubMed ID: 25564564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
    Hutschala D; Kinstner C; Skhirdladze K; Thalhammer F; Müller M; Tschernko E
    Anesthesiology; 2009 Aug; 111(2):356-65. PubMed ID: 19602966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
    Matthews SJ; Lancaster JW
    Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
    Scaglione F; Esposito S; Leone S; Lucini V; Pannacci M; Ma L; Drusano GL
    Eur Respir J; 2009 Aug; 34(2):394-400. PubMed ID: 19213786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.
    Courter JD; Kuti JL; Girotto JE; Nicolau DP
    Pediatr Blood Cancer; 2009 Sep; 53(3):379-85. PubMed ID: 19422028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
    Ampe E; Delaere B; Hecq JD; Tulkens PM; Glupczynski Y
    Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
    Pea F; Poz D; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2006 Aug; 58(2):380-6. PubMed ID: 16735422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR; Burgess DS
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.